Dr M. (Ken) Kengatharan is a co-founder, President and CSO of Altheos, Inc., a co-founder and director of Armetheon, Inc, both biopharmaceutical companies based in South San Francisco, CA and a General Partner at Atheneos Capital, a Bay area based biotech incubator fund. Previously, Dr Kengatharan co-founded Athenagen, Inc (later re-named CoMentis, Inc) which in 2008 completed licensing and drug development collaboration deal with Astellas Pharmaceutical worth $760+ MM with an upfront payment of $100MM. He joined the company in 2005 as VP of Pre-clinical R&D and later became VP of Translational Research and Scientific Affairs. Prior to that, he was a member of staff at Stanford University School of Medicine where he continues his affiliation as a visiting scientist and an advisor to Stanford’s technology incubator SPARK since its founding ~6 years ago. Since the late 1990s, he has been critical to technology asset licensing/acquisition, moving multiple drug candidates from idea to Phase II and for raising more than $130 MM in private equity for five start-up companies. Dr. Kengatharan obtained his Ph.D. in Pharmacology at the William Harvey Research Institute with Nobel laureate Sir John Vane and an MBA (with Distinction) from Durham University in England, where he focused on Biotech Finance and Entrepreneurship.